News

Categories

October 19, 2022

Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody

October 4, 2022

Zymeworks Announces Participation In Upcoming Investor Conferences And Early Research & Development Day

September 4, 2022

Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers

August 4, 2022

Zymeworks Provides Corporate Update And Reports Second Quarter 2022 Financial Results

August 1, 2022

Zymeworks Announces Participation In Upcoming Investor Conferences

July 25, 2022

Zymeworks Announces Oral Presentation Of Data From Phase 1 Study Of Zanidatamab Zovodotin (ZW49) In Solid Cancers At European Society For Medical Oncology (ESMO) Congress 2022 In Paris

July 21, 2022

Zymeworks To Host Second Quarter Results Conference Call

June 27, 2022

Zymeworks Appoints Dr. Paul Moore As Chief Scientific Officer

May 27, 2022

Zymeworks Announces Participation In Upcoming Investor Conference

May 26, 2022

Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022

May 2, 2022

Zymeworks Announces Participation In Upcoming Investor Conferences

April 28, 2022

Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer